SHARE
Press Release
Back
Products

March 10, 2025

Evonik to present sustainability benefits of its portfolio at VIV Asia 2025

Evonik’s participation at the event will showcase how its products and concepts contribute to more efficient and sustainable animal protein production.

  • New life cycle assessments for several products, including MetAMINO® and Ecobiol®, demonstrate Evonik’s progress in transparently minimizing environmental footprints
  • Innovative portfolio that enhances animal health and performance while conserving resources
  • Showcasing feed quality services to boost efficiency and make savings

Evonik is set to highlight the sustainability benefits of its products and services at VIV Asia 2025, reinforcing its commitment to addressing the global food challenge through innovative animal nutrition solutions.

“We’re excited to share our industry-leading approach to sustainability with customers in Asia. Our portfolio not only enhances animal health and performance, but also helps to conserve natural resources and offers considerable cost savings,” said Dr. Gaetano Blanda, head of the Animal Nutrition business line.

Evonik’s participation at the event will showcase how its products and concepts contribute to more efficient and sustainable animal protein production. For instance, the carbon footprint of MetAMINO®, calculated according to an externally certified lifecycle assessment methodology, is approximately 35% lower than the average figure for other industry methionine sources.

For the first time, Evonik has conducted a cradle-to-grave lifecycle assessment of its probiotic product, Ecobiol®, used in broiler production. When Ecobiol® is used to enhance broiler health and performance under challenging conditions, it positively impacts efficiency and sustainability, leading to emission reductions of up to 5%.

“In a rapidly changing world, the need for sustainable animal nutrition solutions is more pressing than ever. Our new life cycle assessments results, in particular, are clear differentiators in the industry,” said Madeline Tan, regional head of Animal Nutrition at Evonik for Asia Pacific.

Evonik Animal Nutrition's management team will host the ‘Sciencing Event,’ which will provide more information to customers about Evonik’s products and its approach to sustainability. The event is scheduled for Thursday, March 13, in VIV Square, Challenger Hall 1.

Visitors to the Evonik booth can learn more about the entire product range of amino acids and specialties for monogastrics and ruminants, and how they help to improve animal health and performance, while reducing the environmental impact of livestock farming. There will also be live demonstrations of Evonik’s AMINONIR® analytical services and AMINOSys® handling solutions, offering customers improved efficiency and significant cost savings.

Evonik can be found at VIV Asia 2025 at Booth 3 – 4010 from 12-14 March, in Bangkok, Thailand.

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.76 billion in 2024 with more than 5,500 employees.  

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.